

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Arthritis Advisory Committee Meeting*

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
October 23, 2015

**QUESTIONS**

---

1. **DISCUSSION:** Discuss the efficacy of the proposed dose of lesinurad 200 mg and whether the decrease in sUA observed would be considered clinically meaningful.
2. **DISCUSSION:** Discuss the safety of the proposed dose of lesinurad 200 mg, with specific focus on renal and cardiovascular safety.
3. **DISCUSSION:** Discuss the dose dependent toxicity of lesinurad in light of the safety profile of the 400 mg dose, and in your discussion, comment on the following:
  - a. Comment on whether the overlapping exposure of the 200 mg and 400 mg doses raises concerns about the potential toxicity of the 200 mg if exposed to a broader population of gout patients post-marketing.
  - b. Comment on whether the justification for once-daily dosing is adequate given that it remains an open question whether a lower nominal dose given more frequently might have provided similar efficacy with a better safety profile.
4. **VOTE:** Overall, do the data provide substantial evidence that lesinurad 200 mg once daily provides a clinically meaningful beneficial effect in the treatment of hyperuricemia associated with gout, in combination with a xanthine oxidase inhibitor?
  - a. Please explain the rationale for your vote.
5. **VOTE:** Is the safety profile of lesinurad 200 mg once daily adequate to support approval of lesinurad for the treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor?
  - a. Please explain the rationale for your vote.
6. **VOTE:** Do you recommend approval of lesinurad 200 mg once daily for the proposed indication of treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor?
  - a. If you voted yes, are there any additional studies recommended post-approval?
  - b. If you voted no, what additional studies are recommended prior to approval?